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Abstract
Background: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-
based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological
tumor response in patients with breast cancer. Secondary purposes were to compare the predictive value of MRI-
based response patterns measured halfway through NAC and after NAC and to measure interobserver variability.
Methods: All consecutive patients treated with NAC for primary invasive breast cancer from 2012 to 2015 and who
underwent breast MRI before, halfway through (and after) NAC were included. All breast tumors were reassessed on
MRI by two experienced breast radiologists and classified into six patterns: type 0 (complete radiologic response);
type 1 (concentric shrinkage); type 2 (crumbling); type 3 (diffuse enhancement); type 4 (stable disease); type 5
(progressive disease). Percentages of tumors showing pathological complete response (pCR), > 50% tumor
reduction and > 50% tumor diameter reduction per MRI-based response pattern were calculated. Correlation
between MRI-based response patterns and pathological tumor reduction was studied with Pearson’s correlation
coefficient, and interobserver agreement was tested with Cohen’s Kappa.
Results: Patients (n = 76; mean age 53, range 29–72 years) with 80 tumors (4 bilateral) were included. There was
significant correlation between these MRI-based response patterns halfway through NAC and tumor reduction on
pathology assessment (reader 1 r = 0.33; p = 0.003 and reader 2 r = 0.45; p < 0.001). Type-0, type-1 or type-2
patterns halfway through NAC showed highest tumor reduction rates on pathology assessment, with > 50% tumor
reduction in 90%, 78% and 65% of cases, respectively. In 83% of tumors with type 0 halfway through NAC, pathology
assessment showed pCR. There was no significant correlation between MRI-based response patterns after NAC and
tumor reduction rates on pathology assessment (reader 1 r = − 0.17; p = 0.145 and reader 2 r = − 0.17; p = 0.146).
In 41% of tumors with type 0 after NAC, pathology assessment showed pCR.
Conclusion: MRI-based response patterns halfway through NAC can predict pathologic response more accurately
than MRI-based response patterns after NAC. Complete radiological response halfway NAC is associated with 83% pCR,
while complete radiological response after NAC seems to be correct in only 41% of cases.
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Background
neoadjuvant chemotherapy and immunotherapy (NAC)
is considered the standard regimen for patients with lo-
cally advanced breast cancer and is increasingly being
used in patients with early-stage breast cancer. Its main
goal is to decrease tumor size [1]. By decreasing tumor
size, NAC may enable patients, who would otherwise
undergo mastectomy, to be treated with breast-
conserving therapy. In patients initially scheduled for
breast-conserving therapy a smaller lumpectomy might
be performed, potentially resulting in improved cosm-
esis. Furthermore, NAC allows in vivo assessment of
tumor response and therefore chemosensitivity. Individ-
ual responses to NAC vary widely, depending on mo-
lecular subtype (i.e. estrogen receptor (ER) negative and
human epidermal growth factor receptor 2 (HER2) posi-
tive tumors respond better) [2], tumor size [3] and treat-
ment regimen [4–6].
In order to achieve the maximum surgical advantage
from NAC, it is essential that tumor response and re-
sidual tumor can be evaluated correctly prior to surgery.
Studies show that magnetic resonance imaging (MRI) is
the most accurate in determining residual disease after
NAC compared to physical examination, mammography
and ultrasound [7]. Unfortunately, MRI might both over-
estimate or underestimate residual tumor size. The over-
all loss of vital tumor cells might not always be reflected
by a reduction in tumor diameter as fibrous stroma
might persist and even be enhanced on MRI [8]. Tumor
size assessment itself on MRI might also be challenging,
as NAC causes various histopathological changes in
tumor cellularity, causing some tumors to show concen-
tric shrinkage patterns, while others may crumble
(“fragmentation”) into scattered islands of tumor cells.
In the latter case, a response is present, but this might
not be expressed in simply measuring tumor size, as
these individual scattered foci cannot be measured inde-
pendently on MRI.
Previous research shows that triple negative breast tu-
mors regress significantly more often as a shrinking
mass than HER2 positive and ER positive/HER2 negative
tumors [9]. In addition, Kim et al. demonstrated that
there is a significant difference in MRI-based response
patterns after NAC between pathological responders and
non-responders [8]. However, these studies analyzed re-
sponse patterns after completion of NAC. At this point,
changes in treatment regimen are no longer possible.
Furthermore, the ACRIN study suggests that MRI early
in NAC treatment is a stronger predictor of pathological
response than MRI after NAC [10]. Hence, studying the
association between response patterns on MRI during
NAC and final histopathological response (when switch-
ing to a cross-resistant NAC in cases with poor
(predicted) response might still be possible) could have
more clinical implications. To our knowledge, no study
has tested correlation between MRI-based response pat-
terns halfway through NAC and pathological response.
Therefore, the main goal of this study was to analyze
MRI-based response patterns halfway through NAC and
to investigate their role as an early therapy response pre-
dictor. Secondary goals were to compare the predictive
value of MRI-based response patterns measured halfway
through NAC to after NAC and to compare preoperative
tumor diameter on breast MRI with tumor size on
pathology assessment to evaluate residual tumor assess-
ment in different MRI-based response patterns. Finally,
we evaluated interobserver agreement for assessment of
MRI-based response patterns and tumor diameter.
Methods
Patient selection
We included all consecutive patients who were treated
with NAC for histologically proven primary invasive
breast cancer between January 2012 and June 2015, and in
whom tumor response was monitored with MRI in the
Maastricht University Medical Center+ (MUMC+). In this
hospital, standard response monitoring with MRI was per-
formed before, halfway through and after NAC. MRI after
NAC was often not performed in the case of complete
radiological response halfway through NAC or in the case
of mastectomy. Patients who underwent surgery after
NAC and underwent at least two MRI examinations were
included in this study, provided that the first MRI was
performed at baseline, i.e. prior to NAC, and the second
MRI after completion of at least three cycles of chemo-
therapy. Exclusion criteria were unknown ER, progester-
one receptor (PR), or HER2 status prior to NAC, previous
ipsilateral breast surgery, previous systemic treatment
because of contralateral breast cancer and presence of
distant metastasis at time of diagnosis.
MRI protocol
Breast MRI was performed on a 1.5 T scanner using a dedi-
cated bilateral 16-channel breast coil (Philips Healthcare,
Best, The Netherlands). As contrast agent, gadobutrol
(Gadovist®, Bayer Health Care, Germany) was automatically
injected through a catheter in the antecubital vein at
0.1 mmol/kg body weight, followed by a saline flush.
The imaging aprotocol consisted of two-dimensional T2-
weighted images without fat suppresion, dynamic contrast-
enhanced fat-saturated T1-weighted images using gadobutrol
as a contrast agent, and diffusion weighted imaging (DWI).
Imaging parameters can be found in Additional file 1.
Imaging analysis and tumor response pattern assessment
on MRI
Two experienced breast radiologists (JBH and RMM), with
7 and 12 years of experience respectively, independently
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reviewed all breast MRI scans. They were blinded to patho-
logical tumor characteristics and pathological outcome
after surgery.
MRI-based response patterns of breast carcinomas dur-
ing and after NAC were classified into six categories
adapted from the classification suggested by Kim et al. [8]
(Fig. 1): type 0 (complete radiologic response); type 2
(concentric shrinkage > 3 mm without surrounding
lesions); type 2 (crumbling: shrinkage with residual multi-
nodular lesions); type 3 (diffuse contrast enhancement in
whole quadrants); type 4 (stable disease, i.e. no response,
shrinkage < 3 mm or increase < 3 mm); type 5 (progressive
disease, i.e. increase in tumor size > 3 mm or new lesions).
A short introduction about the MRI-based response
patterns and a test case were provided for both readers.
Furthermore, tumor size was determined by measuring
the largest diameter of the largest breast lesion on the T1-
weighted MRI sequence at peak enhancement (i.e. first dy-
namic phase after contrast injection) in one view. Readers
were allowed to use multiplanar reconstructions to assess
the largest tumor diameter.
Treatment
All patients received systemic treatment and underwent
surgery at the MUMC+. NAC treatment consisted of two
possible regimens. All patients with HER2-negative
tumors received six cycles of docetaxel, doxorubicin and
cyclophosphamide. HER2-positive tumors were treated
with four cycles of doxorubicin and cyclophosphamide
followed by four cycles of docetaxel and trastuzumab.
After NAC, breast conserving therapy or mastectomy and
surgery of the ipsilateral axilla (sentinel lymph node
biopsy in the case of node-negative (N0) and axillary
lymph node dissection in the case of N+) were performed.
Histopathological assessment
All pre-treatment core biopsies and post-treatment surgi-
cal specimens were routinely processed. Histopathological
analyses were performed by an experienced breast path-
ologist in accordance with our national breast cancer
guideline at the time of diagnosis [11].
Pre-treatment core biopsies were used for grading
(according to the modified Bloom-Richardson grading
system) and determining receptor status of the tumor.
Hormone receptor status, i.e. ER and PR status, was
determined by immunohistochemical evaluation and inter-
preted according to national guidelines in which > 10% of
tumor staining is used as a positive cutoff. HER2 status
was determined using fluorescence in situ hybridization
(FISH) analysis to detect gene amplification in biopsied tis-
sue and was analyzed according to the ASCO CAP guide-
lines [12]. Tumors were stratified into molecular subtypes
based on immunohistochemical evaluation and FISH.
Hormone receptor status was considered positive (ER+)
when ER and/or PR status was positive and negative (ER-)
if both were negative. There were four molecular subtypes:
ER+/HER2-, ER+/HER2+, ER-/HER2+ and ER-/HER2-.
Histopathological measurement of residual tumor size,
which is considered to be the gold standard, was per-
formed in fresh tissue and correlation was tested micro-
scopically in formalin-fixed, paraffin-embedded tissue.
This assessment only included invasive foci, not ductal
carcinoma in situ (DCIS). DCIS was measured separ-
ately. Pathological dimensions were determined using
the longest diameter of the residual tumor or in the case
of multifocal disease, the primary index tumor. There-
after, specimens were fixed with formalin.
Histopathological response of the tumor to treatment
was evaluated based on reduction of tumor cellularity,
using the Pinder classification (Table 1). Pathological
complete response (pCR) was defined as absence of
macroscopic and microscopic evidence of invasive tumor
and absence of ductal carcinoma in situ (DCIS).
For this study, patients with Pinder classification 2iii
or 3 (i.e. < 50% or no regression in tumor cells) were cat-
egorized as non-responders, while patients with Pinder
Fig. 1 Magnetic resonance imaging (MRI)-based response patterns of breast carcinomas on breast MRI halfway through and after
neoadjuvant chemotherapy
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classification 1i–2ii (i.e. ≥ 50% regression in tumor cells)
were classified as pathological responders.
Statistical analysis
Pearson’s correlation coefficient was used to test correl-
ation between the MRI-based response patterns (halfway
through and after NAC) and pathological response after
NAC. In case multifocal disease was present, the lesion
with the largest dimensions on baseline MRI, considered
to be the primary index tumor, was included for statis-
tical analysis. Interobserver agreement between both
readers classifying the response according to the six
MRI-based patterns was calculated with Cohen’s Kappa
[13]. The distribution of the MRI-based response
patterns in the different breast cancer subtypes was
mapped. Mean tumor size and agreement between both
readers was calculated. Pearson’s correlation coefficient
was also used to test correlation between tumor size on
MRI after NAC and pathologically assessed tumor size
(gold standard). When a difference of more than 5 mm
between both measurement techniques or between both
readers was observed, this was considered to be clinic-
ally relevant. A p value <0.05 was considered to be sta-
tistically significant. All analyses were performed using
Statistical Package for the Social Sciences (SPSS), version
22.0 (IBM Corporation, Armonk, NY, USA).
Results
A total of 76 patients with 80 primary breast tumors
(4 bilateral) were included. All patients underwent a
breast MRI exam before and halfway through NAC; 57 pa-
tients also underwent a breast MRI exam after completion
of NAC. Baseline characteristics are shown in Table 2.
Mean age was 53 years (range 29–72). Most tumors (89%)
were classified as invasive carcinoma of no special type
(NST) and 11% were lobular carcinomas. Considering
receptor status, most tumors (60%) were ER/PR positive
and HER2 negative (Table 2).
In ten tumors pathological tumor response was assessed
with the Miller and Payne grading system and in five of
them this classification could not be converted to the
Pinder classification. Therefore, these five patients could
not be included in any pathological response analyses, but
were included in the evaluation of residual tumor size.
Furthermore, since reader 1 did not classify any tumors as
Table 1 Pinder classification
Pinder classification Explanation
1i Pathological complete response,
no DCIS
1ii Pathological complete response,
including DCIS
2i Response > 90% (or < 10% invasive
tumor left)
2ii Response of 50–90% (or 10–50%
invasive tumor left)
2iii Response < 50% (or > 0% invasive
tumor left)
3 No signs of response
DCIS ductal carcinoma in situ
Table 2 Baseline characteristics
Characteristic Number Percentage
Age, years
Mean (n = 76) 53
Range 29–72
T-stage prior to NAC
T1 13 16
T2 46 58
T3 15 19
T4 5 6
Tx 1 1
N-stage prior to NAC
N0 49 61
N1 22 28
N2 3 4
N3 6 8
Histology
Invasive carcinoma NST 71 89
Lobular carcinoma 9 11
DCIS
Present 21 26
Absent 45 56
Unknown 14 18
Subtype by receptor status
ER/PR+ HER2+ 13 16
ER/PR+ HER2- 48 60
ER- PR-HER2+ 6 8
ER-PR-HER2- 13 16
Grade
1 2 3
2 35 44
3 25 31
Unknown 18 23
Surgical method
Mastectomy 46 58
Lumpectomy 34 43
Abbreviations: T-stage tumor stage, NAC neoadjuvant chemotherapy and
immunotherapy, N-stage nodal stage, NST no special type, DCIS ductal
carcinoma in situ, ER estrogen receptor, PR progesterone receptor, HER2
human epidermal growth factor receptor 2
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showing diffuse enhancement (type 3), most analysis did
not include the type 3 response pattern.
Baseline MRI - tumor diameter and interobserver
agreement
Mean baseline tumor diameter was 30 mm (range
11–76 mm) according to reader 1 and 32 mm (range 12–
118 mm) according to reader 2. At baseline tumor diam-
eter differed more than 5 mm between both readers in 28
tumors (35%), but in only 5 of them (6%) this difference
resulted in a difference in clinical tumor stage
MRI halfway through NAC - response patterns and
interobserver agreement
Figure 2 shows an example of a type 1 response
(concentrically shrinking tumor) and of a type 2
response (crumbling tumor).
As shown in Tables 3 and 5, tumors showing a type-0
response (complete radiologic response) on MRI halfway
through NAC have the best pathologic tumor response
(90% had > 50% tumor reduction and 83% had pCR).
Patients with a type-2 response (crumbling tumors)
less often had > 50% tumor reduction (65% vs 78%) and
less often had pCR (14% vs 26%) than patients with
tumors with a type 1 response (concentric shrinking)
halfway through NAC. Similar rates were seen for tumor
diameter reduction > 50% in patients with type-1 and a
type-2 response halfway through NAC (40% vs 37%).
There was weak but significant correlation between
the MRI-based response patterns halfway through NAC
and pathological tumor reduction; lower MRI response
patterns (type 0–2) were related to higher pathological
tumor reduction rates than higher MRI response
patterns (type 3–5) (r = 0.33; p = 0.003 for reader 1 and
r = 0.445; p < 0.001 for reader 2).
Among patients with pCR, nearly all tumors with pCR
(n = 16 (20%)) showed a type 0, 1 or 2 response on MRI
halfway through NAC (except for one tumor classified
as type 4 by reader 2). Considering interobserver agree-
ment, in 40/80 cases (50%) both readers classified the
tumor into the same MRI-based response pattern half-
way through NAC; in the other half of the cases they
disagreed. Interobserver agreement between reader 1
and 2 was therefore considered fair (κ = 0.301).
Halfway through NAC mean tumor sizes determined on
MRI by readers 1 and 2 were 19 mm (range 0–54 mm)
and 24 mm (range 0–119 mm), respectively. Halfway
through NAC tumor there were diameter differences > 5
mm between the two readers’ assessments in 25 patients
(31%). Most differences in tumor diameter were in
tumors classified as crumbling (58%) and occurred in
around 25% (21–33%) of tumors with the other MRI-
response patterns.
MRI after NAC - response patterns and interobserver
agreement
As shown in Tables 4 and 5, tumors showing a type-0
response (complete response) after NAC had the best
pathological tumor response (96% had > 50% tumor
reduction and 41% had pCR) followed by both the
type 2 (crumbling) and the type 1 response (concentric
shrinking tumors), which seem to downsize at similar
rates on pathological assessmenbt (Tables 4 and 5).
When we look further into the type-0 response after
NAC, we see that 10 out of 16 tumors classified as
having a type-0 response (complete radiological re-
sponse) by one or both readers on MRI after NAC still
showed residual tumor on pathological assessment.
None of these 10 tumors were triple negative and 2 were
lobular carcinomas.
There was no significant correlation between the MRI-
based response patterns after NAC and pathological re-
sponse after NAC (r = − 0.170; p = 0.145 for reader 1 and
r = − 0.169; p = 0.146 for reader 2). Among patients with
pCR, we observed that out of 16 patients with pCR, 7 did
not undergo MRI after NAC: out of the 9 patients that
did, 4 was classified as type 0 by both readers (complete
response, true negatives), another was classified as type 0
by reader 1 but as type 3 by reader 2. The other four pa-
tients were classified as a type-1 or type-2 response and
one was even classified as having type-4 (reader 1) and
type-3 (reader 2) responses.
Fig. 2 Example of a tumor that shrinks concentrically: magnetic
resonance imaging (MRI) before neoadjuvant chemotherapy and
immunotherapy (NAC) (a) and halfway through NAC (b); and a tumor
that crumbles: MRI before NAC (c) and halfway through NAC (d)
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Considering interobserver agreement, in 27/57 cases
(47%) both readers classified the tumor into the same
MRI-based response pattern halfway through NAC. In
the other 53% they disagreed. Interobserver agreement
between reader 1 and 2 was therefore also considered
fair (κ = 0.312).
The mean residual tumor sizes on MRI according to
readers 1 and 2 were 13 mm (range 0–50 mm) and 23
mm (range 0–105 mm), respectively. Mean pathological
tumor size after NAC was 21 mm (range 0–105 mm).
Tumor diameter after NAC differed by more than 5 mm
between the two readers in 22 patients (39%). Tumor
diameter differences between readers were least com-
mon in complete radiological responders (20%) and were
observed in 35%, 40%, 47% and 75% of patients with
types 1, 2, 4 and 5 MRI-response patterns, respectively.
Furthermore, tumor diameter differed by more
than 5 mm between reader 1 and pathological assess-
ment in 35 tumors (61%, of which size was underesti-
mated in 66%) and between reader 2 and pathological
assessment in 33 tumors (58%, of which size was underes-
timated in 42%). For reader 1, most differences in meas-
urement were in tumors classified as concentric shrinking
tumors (70%) followed by the crumbling tumors (64%).
For reader 2, most of the differences in measurement were
in tumors classified as diffuse enhancing tumors (78%)
followed by concentric shrinking (63%) and crumbling
(53%) tumors.
Table 3 MRI-based response patterns of breast carcinomas on breast MRI halfway through NAC and pathological response per
MRI-based response pattern
Reader 1 Reader 2
Number
(percentage)
Tumor
response > 50%
Diameter
reduction > 50%
pCR Number
(percentage)
Tumor
response > 50%
Diameter
reduction > 50%
pCR
Complete radiologic
response (type 0)
5 (7%) 4/5 (80%) 4/5 (80%) 4/5 (80%) 7 (9%) 7/7 (100%) 6/7 (86%) 6/7 (86%)
Concentric shrinkage
(type 1)
38 (51%) 30/38 (79%) 14/38 (37%) 9/38 (24%) 22 (29%) 17/22 (77%) 8/22 (36%) 6/22 (27%)
Crumbling (type 2) 21 (28%) 13/21 (62%) 8/19a (42%) 3/21 (14%) 24 (32%) 16/24 (67%) 9/24 (38%) 3/24 (13%)
Diffuse enhancement
(type 3)
0 (0%) n.a. n.a. n.a. 3 (4%) 3/3 (100%) 0/2a (0%) 0/3 (0%)
Stable disease
(type 4)
11 (15%) 5/11 (55%) 4/11 (36%) 0/11 (0%) 18 (27%) 9/18 (50%) 7/17a (41%) 1/18 (6%)
Progressive disease
(type 5)
0 (0%) n.a. n.a. n.a. 1 (1%) 0/1 (0%) 0/1 (0%) 0/1 (0%)
Total 75 (100%) 52/75 (69%) 30/73a (41%) 16/75 (21%) 75 (100%) 52/75 (69%) 30/73a (41%) 16/75 (21%)
Abbreviations: MRI magnetic resonance imaging, pCR pathological complete response, n.a. not applicable
aIn two tumors no diameter assessment was possible on baseline MRI
Table 4 MRI-based response patterns of breast carcinomas on breast MRI after NAC and pathological response per MRI-based
response pattern
Reader 1 Reader 2
Number
(percentage)
Tumor
response > 50%
Diameter
reduction > 50%
pCR Number
(percentage)
Tumor
response > 50%
Diameter
reduction > 50%
pCR
Complete radiologic
response (type 0)
13 (23%) 12/13 (92%) 7/12a (58%) 5/13 (38%) 9 (16%) 9/9 (100%) 5/8a (63%) 4/9 (44%)
Concentric shrinkage
(type 1)
19 (33%) 11/19 (58%) 7/19 (37%) 2/19 (11%) 8 (14%) 5/8 (63%) 4/8 (50%) 2/8 (25%)
Crumbling (type 2) 11 (19%) 7/11 (64%) 5/11 (45%) 1/11 (9%) 15 (26%) 11/15 (73%) 6/15 (40%) 1/15 (6%)
Diffuse enhancement
(type 3)
0 (0%) n.a. n.a. n.a. 10 (18%) 8/10 (80%) 5/10 (50%) 2/10 (20%)
Stable disease (type 4) 13 (23%) 6/13 (46%) 2/13 (15%) 1/13 (8%) 14 (25%) 4/14 (29%) 1/14 (7%) 0/14 (0%)
Progressive disease
(type 5)
1 (2%) 1/1 (100%) 0/1 (0%) 0/1 (0%) 1 (2%) 0/1 (0%) 0/1 (0%) 0/1 (0%)
Total 57 (100%) 37/57 (65%) 21/56a (38%) 9/57 (16%) 57 (100%) 37/57 (65%) 21/56a (38%) 9/57 (16%)
Abbreviations: MRI magnetic resonance imaging, NAC neoadjuvant chemotherapy and immunotherapy, pCR pathological complete response
aIn one tumor no diameter assessment was possible on baseline MRI
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Surgery and MRI-based response patterns
Mastectomy was performed in 46 patients and breast
conserving therapy in 34 patients. In 7/80 patients the
tumor was not completely removed. Characteristics of
these seven tumors are displayed in Table 6. There was no
significant correlation between MRI-based response
patterns halfway through or after NAC and incomplete
resection (even though types 1 and 4 seem to predomin-
ate). In two of these tumors, the tumor diameter was
underestimated by more than 5 mm by both readers, and
was underestimated in three tumors by one reader.
Subtype and MRI-based response patterns
As shown in Table 7, 16% of tumors were classified as
ER + HER2+, 60% as ER + HER2-, 8% as ER-HER2+ and
16% as ER-HER2-. Numbers were too small for subtype
analyses but we observed that only type 0 or 1 MRI pat-
terns halfway through NAC led to pCR for ER + HER2-
tumors while in other subtypes a type 2 (or exceptionally
type 4) tumor could become classified as pCR halfway
through NAC.
Discussion
One of the main reasons for starting neoadjuvant
chemotherapy in patients with breast cancer is to de-
crease tumor volume. Individual responses to NAC vary,
depending on molecular subtype, tumor size and treat-
ment regimen, but also depending on factors that are
still unknown. Predicting individual response to NAC re-
mains difficult. Enabling response prediction during
NAC would help determine the usefulness of NAC and
may lead to alterations in treatment regimen or per-
forming surgery earlier than initially planned. To further
explore the possibilities of response prediction, the main
goal of this study was to investigate the correlation be-
tween six MRI-based response patterns halfway through
NAC and pathological evidence of tumor response.
Secondary goals were to compare the predictive value
of MRI-based response patterns measured halfway
through to after NAC and to evaluate interobserver
agreement. Furthermore, to achieve the maximum surgi-
cal advantage from NAC, it is essential that tumor re-
sponse and residual tumor are assessed correctly before
surgery. In this study, we compared preoperative tumor
diameter on MRI with pathological tumor size and eval-
uated the assessment of residual tumor in different
MRI-based response patterns after NAC.
In this study, there was significant correlation between
MRI-based response patterns measured halfway through
NAC and pathological evidence of tumor reduction
(r = 0.33; p = 0.003 for reader 1 and r = 0.45; p < 0.001 for
reader 2). Tumors with a type-0 response (complete radio-
logical response) halfway through NAC had a 90% chance
of pathological evidence of tumor reduction > 50% and
83% chance of pCR. Tumors with a type-2 response
(crumbling tumors) less often had tumor reduction > 50%
(65% vs 78%) and less often had pCR (14% vs 26%) than
tumors with a type-1 response (concentric shrinking)
halfway through NAC. Tumors with a type-4 (stable
disease) or type-5 response (progression) halfway
through NAC had the lowest chances of tumor regres-
sion. A tumor with a type-4 response (stable disease)
halfway through NAC only had a 3% chance of being
classified as pCR.
Since nearly all tumors with pCR (n = 16 (20%)) had a
type 0, 1 or 2 response halfway through NAC (except for
one tumor classified as type 4 by reader 2), we can
conclude that for a tumor to have pCR, a type 0, 1 or 2
response is required halfway through NAC.
There was no correlation between MRI-based response
patterns measured after NAC (prior to surgery) and patho-
logical evidence of tumor reduction (r = − 0.170; p = 0.145
for reader 1 and r = − 0.169; p = 0.146 for reader 2). The
greatest pathological tumor reduction was observed in tu-
mors with a type-0 response after NAC (96% had tumor
Table 5 Mean percentages of pathological response per MRI-based response pattern (mean percentage of reader 1 and 2) halfway
through and after NAC
MRI halfway through NAC MRI after NAC
Percentage of
total (N = 75)
Tumor
response > 50%
Diameter
reduction > 50%
pCR Percentage of
total (N = 57)
Tumor
response > 50%
Diameter
reduction > 50%
pCR
Complete radiologic response
(type 0)
8% 90% 83% 83% 20% 96% 61% 41%
Concentric shrinkage (type 1) 40% 78% 37% 26% 24% 61% 44% 18%
Crumbling (type 2) 30% 65% 40% 14% 23% 69% 43% 8%
Diffuse enhancement (type 3) 2% n.a. n.a. n.a. 9% n.a. n.a. n.a.
Stable disease (type 4) 21% 53% 39% 3% 24% 38% 11% 4%
Progressive disease (type 5) 1% n.a. n.a. n.a. 2% 50% 0% 0%
Total 100% 69% 41% 21% 100% 65% 38% 16%
Abbreviations: MRI magnetic resonance imaging, NAC neoadjuvant chemotherapy and immunotherapy, pCR pathological complete response, n.a. not applicable
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reduction > 50% and 41% had pCR) followed by type 1
(concentric shrinking) (61% had tumor reduction > 50%
and had 18% pCR) and type 2 response (crumbling tu-
mors) (69% had tumor reduction > 50% and 8% had pCR).
This implies that even if the radiologist no longer detects
suspicious lesions (type 0) on MRI after NAC, around 60%
of the patients still have invasive carcinoma or DCIS on
pathological examination. In conclusion, as we hypothe-
sized, the MRI-based response patterns measured halfway
through NAC correlate better with pathological tumor
response than MRI-based response patterns measured
after NAC.
In our study both radiologists performed an independ-
ent reading and we observed fair interobserver agreement
halfway through and after NAC, for both the classification
of MRI-based response patterns and for tumor diameter
measurements. Only half of the tumors were classified as
the same MRI-based response pattern, and tumor
diameter differences >5 mm occurred in 31–61% of cases,
consisting of both underestimation and overestimation of
size, and occurring in all MRI-based response patterns.
Nevertheless, both readers’ MRI-based response classifica-
tions correlated similarly with pathological response. Only
in 7/80 patients was the tumor not completely removed
(and 2/7 of these patients had mastectomies). The latter
might mean that both experienced readers have different
strengths leading to an equal outcome. Hence, this might
imply that getting better consensus about how to classify
the tumors could still improve the results. This study high-
lights challenges and limitations in predicting response to
NAC and determining residual disease in breast cancer.
Comparison with other studies
In a recent study by Ballesio et al. (n = 51) the authors
found that 65% of tumors with the concentric pattern
halfway through NAC (n = 13; p < 0.001) had pCR, while
none of the non-responders had the concentric pattern
[14]. This is partly in agreement with our results. We
found that 24% of the tumors with the type-1 pattern
had pCR and 83% of tumors with the type-0 pattern
which assumable together form the concentric pattern
of their study. However, the percentage of non-
responders with a type 1 pattern was 22% in our study.
This difference may be due to the smaller number of pa-
tients (n = 51 versus n = 80) and the different choice of
the MRI-based response patterns used. They only used
three response patterns: concentric, nodular and mixed.
This way they assumed all tumors shrink during NAC,
while in our study 25% of tumors showed a stable response
or progression. They also did not include a complete radio-
logical response (i.e. pattern 0) while this was the group of
patients with the strongest correlation with pCR in our
study. We did not include a mixed pattern because the
Table 6 Characteristics of incompletely removed tumors (tumor-positive margins)
Tumor
type
MRI-pattern halfway
through NAC (R1)
MRI-pattern halfway
through NAC (R2)
MRI pattern
after NAC (R1)
MRI pattern
after NAC (R2)
Tumor size
after NAC (R1)
Tumor size
after NAC (R2)
Surgery Pathological
tumor size
1 Ductal 1 1 1 1 18 23 Lumpectomy 19
2 Lobular 0 2 MRI not
performed
MRI not
performed
MRI not
performed
MRI not
performed
Mastectomy 105
3 Ductal 1 1 1 3 4 22 Lumpectomy 17
4 Ductal 2 4 4 4 20 15 Mastectomy 80
5 Ductal 1 2 1 4 23 20 Lumpectomy 40
6 Ductal 1 1 1 4 8 15 Lumpectomy 17
7 Ductal 1 4 4 4 6 17 Lumpectomy 21
Abbreviations: MRI, magnetic resonance imaging, NAC neoadjuvant chemotherapy and immunotherapy, R1 reader 1, R2 reader 2
Table 7 Number of tumors per subtype, number of tumors per subtype with pathological complete response and their MRI-based
response patterns
Subtype Number of tumors
(percentage)
Number with
pCR (percentage)
MRI patterns halfway
through NAC in tumors
showing pCR (R1 and R2)
MRI patterns after NAC
in tumors showing pCR
(R1 and R2)
ER+/HER2+ 13 (16%) 3 (23%) 0, 1, 2, 4 0, 1, 2
ER+/HER2- 48 (60%) 4 (8%) 0, 1 0, 1
ER-/HER2+ 6 (8%) 3 (50%) 0, 1, 2 0, 1, 2
ER-/HER2- 13 (16%) 6 (46%) 0, 1, 2 0, 3, 4
Total 80 (100%) 16 (20%) 0, 1, 2, 4 0, 1, 2, 3, 4
Abbreviations: MRI magnetic resonance imaging, pCR pathological complete response, NAC neoadjuvant chemotherapy and immunotherapy, ER estrogen receptor,
HER2 human epidermal growth factor receptor 2, R1 reader 1, R2 reader 2
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difference between “crumbling” and “crumbling and
shrinking” might be minute and mostly subjective.
Two other studies studying MRI-based response pat-
terns looked at MRI-based response patterns after NAC.
The study of Golden et al. (only triple negative tumors,
n = 60) had the same MRI-based response categories ex-
cept they did not include diffuse enhancement (type 3)
[15]. Even though our population only included 13 triple
negative tumors, we found similar results in that MRI-
based response patterns after NAC cannot successfully
predict pathological outcome. Finally, our study was
predominantly based on the study of Kim et al. (n = 55
(56 lesions)) [8], expanding and adjusting their classifica-
tion. Like their results, concentric shrinking and crum-
bling tumors were more frequently observed in the
pathological responder group. They more often noted the
diffuse enhancing tumors in the non-responder group. As
mentioned earlier, our number of diffuse enhancing tu-
mors was too small to analyze. One of the most important
additions in our study, as compared to their classification,
was the definition of a complete response group (i.e. pat-
tern 0), since this most accurately predicts pathological re-
sponse. Furthermore, compared to their study, we tested
the classification halfway through NAC in a larger cohort,
showing stronger correlation to pathological response
than after NAC.
One possible explanation for the better prediction of
pathological response by MRI halfway through NAC
than after NAC is that taxanes might suppress MRI en-
hancement irrespective of the cytotoxic activity. This
finding was reported by Schrading et al. and since in our
patient cohort taxanes were also only given during the
second half of treatment, this could be a plausible ex-
planation. Furthermore, as already shown by earlier
studies, our study also shows that this might be false nega-
tive, especially when lobular carcinomas are classified as
complete responders. Furthermore, the two triple negative
tumors classified as type 0, were both true negatives.
Strengths, limitations and future implications of this
study
We studied the MRI patterns in the largest group of pa-
tients so far and only one comparable study was per-
formed recently. Furthermore, this is the first study to
look at interobserver agreement in MRI-based response
patterns. The other studies that looked at MRI-based re-
sponse patterns all performed a consensus reading of
two radiologists. Therefore, none of them could test in-
terobserver agreement. High interobserver agreement is
important and desirable when we want to implement
these MRI-based response patters in broad clinical prac-
tice. As mentioned earlier, we observed low interob-
server agreement for the MRI-based response patterns.
To increase interobserver agreement, a group of
experienced radiologists should reach consensus about
which tumors to classify under which MRI-based response
pattern. Furthermore, it would also be desirable to reduce
the interobserver differences in tumor diameter measure-
ments. This for example could be done by looking into
the strengths and weaknesses of experienced or even dedi-
cated breast radiologists and making current practicing ra-
diologists aware of these strong points and pitfalls.
One of the limitations of this study is that, as in the clin-
ical setting, tumors were only measured on one slice on
MRI and in one cutting direction by the pathologist. If the
cutting direction was different from the MRI slice direc-
tion, the tumor diameter might differ. Another possible
factor influencing diameter differences is that residual
DCIS was excluded from the size estimation on patho-
logical assessment, whereas this might have been visible
on MRI, and therefore might have been included on the
MRI evaluations. Furthermore, if multifocal disease was
present, only the lesion with the largest dimensions on
baseline MRI, considered to be the index tumor, was in-
cluded for statistical analysis. Therefore, these results
might not be applicable to multifocal tumors.
Future research should look into these MRI-based re-
sponse patterns in an even larger group of patients with
breast cancer. This way subgroup analyses can be per-
formed to look at the differences in response patterns in
the different subtypes of breast cancer. And last, we have
to perform further research combining all response pa-
rameters (including subtypes, these MRI-based response
patterns identified halfway through NAC and other pa-
rameters proven to help in response prediction, like MRI
enhancement patterns and (semi-) automated tumor
volume assessment) [16], to form a panel of biomarkers
that enables individual response prediction.
Conclusion
In patients with breast cancer undergoing NAC, tumor re-
duction > 50% was seen in about 70% of tumors and re-
duction in diameter > 50% was seen in about 40% of
tumors. MRI-based response patterns halfway through
NAC predicted pathological response more accurately
than MRI-based response patterns after NAC. A complete
radiological response halfway through NAC was associ-
ated with 83% pCR while a complete radiological response
after NAC only seemed to be correct in 41% of the cases.
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